LEADERSHIP IN FIBROSIS: Promedior's New Therapeutic Paradigm

Armed with unique and comprehensive insights into monocyte biology, Promedior is creating a therapeutic platform based on pentraxin-2 (PTX-2) , a naturally-occurring protein shown to regulate a number of important immune, inflammatory, and fibrotic processes in the body. Promedior drug developers have discovered a natural pentraxin-based mechanism through which the body regulates the fundamental innate immune response at the source by controlling monocyte and monocyte-derived cell differentiation and activation mechanisms. Promedior’s therapeutics use this natural mechanism to specifically recognize a site of injury and control how the monocytes react to damaged tissue, stimulating monocyte differentiation into a beneficial, pro-resolution regulatory state and preventing differentiation into pathologic fibrocytes and M2 macrophages.

PTX-2 Naturally Targets Monocytes: Pentraxin-2 (PTX-2) simultaneously controls the initiation and progression of fibrosis and promotes healing and resolution. In the presence of PTX-2, recruited monocytes are signaled by the PTX-2 coated cellular debris to differentiate into regulatory macrophages, locally shifting the cellular equilibrium to resolution and healing. The regulatory macrophages secrete IL-10 to inhibit myofibroblast-driven scar tissue production and shift the ratio of TIMP/MMP expression resulting in increased break down of scar tissue. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of MMP.

[ back to top ]